Introduction
============

Worldwide, hepatocellular carcinoma (HCC) is the fifth most common cancer in males and the seventh in females and is the third most common cause of cancer death [@B1]. The incidence of HCC varies greatly according to the geographic area; the highest incidence of HCC in the world is reported by registries in Asia and Africa. Approximately 85% of all liver cancers occur in these areas, with Chinese registries alone reporting over 50% [@B2]. HCC in China ranks as the second most common cause of cancer death in males and the third in females. The mortality rate from HCC is higher in males (37.4/100,000) than in females (14.3/100,000) [@B3]. The major risk factors for HCC in Asia and Africa are chronic hepatitis B virus (HBV) infection and aflatoxin B1 (AFB1) exposure. HBV is responsible for 75 to 80% of virus-associated HCC [@B4].

However, the mechanisms of the oncogenesis of HBV remain obscure. Nonetheless, mutations in the viral genome associated with tumour development recently have become a major focus of research. The precore mutation (G~1896~A), mutations in enhancer II (C~1653~T) and the BCP (T~1753~V and the double mutations, A~1762~T, G~1764~A), and deletions in the pre-S region have been reported to be associated with the development of HCC [@B5]-[@B11]. Perhaps the most convincing association is with HBV with the double mutations in the BCP; this has been confirmed by several cohort studies, suggesting that the double mutations are an aetiological factor of HCC [@B8], [@B12]-[@B13].

In addition to HBV and AFB1 exposure, host factors may play a role in the development of HCC. There have been a few genome-wide association studies (GWAS) conducted on the genetic susceptibility to HBV-related HCC. Various single nucleotide polymorphisms (SNPs), such as rs7574865 at STAT4, rs9275319 at HLA-DQ and rs12682266, rs7821974, rs2275959, rs1573266 at chromosome 8p12, have been found to be associated with the development of HBV-related HCC [@B14]-[@B15]. Combined analyses of copy number variation (CNV), individual SNPs, and pathways suggests that HCC susceptibility is mediated by germline factors affecting the immune response and differences in T-cell receptor processing [@B16].

When we established the Long An cohort in 2004, we found that about half of the HBV-infected individuals have BCP double mutations (A~1762~T, G~1764~A) in the viral genome and more than 93% of HCC cases occurred in those with BCP double mutations[@B8]. Why are BCP double mutations selected in a subset of HBV carriers? The answers may be helpful in understanding the pathogenesis of HCC. It has been reported from candidate-gene studies that host genetic polymorphisms are associated with the immune selection of HBV mutations [@B17]. This phenomenon may also be seen in other viruses, such as HIV-1 [@B18]. Therefore, we carried out a genome-wide association study (GWAS), based on the Long An cohort, to search for a genetic basis of the selection of HCC-related, HBV BCP mutations and which may potentially identify novel related SNPs.

Materials and Methods
=====================

Study subjects
--------------

The study subjects were recruited from the Long An cohort, which was described previously [@B8]. The cohort was recruited in early 2004 from agricultural workers aged 30-55 living in the rural area of Long An county, Guangxi, China, using stratified sampling. This cohort comprises 2258 HBsAg-positive study subjects, including a group (1261) with BCP double mutations and a wild type BCP group (997). They were further stratified into the male mutant (702) and wild type (561) groups and female mutant (559) and wild type (436) groups. When we recruited study subjects for this study, we retested BCP sequence of HBV of each subject in 2014. The selection criterion is that they were infected with HBV with the same BCP sequence as at baseline.

Informed consent in writing was obtained from each individual. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki and has been approved by the Guangxi Institutional Review Board.

Serological Testing
-------------------

Sera were tested for HBV serological markers using enzyme immunoassays and AFP using a Diagnostic Kit for the Quantitative Determination of Alpha-feto-protein (ELISA) (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Beijing, China) according to the manufacturer\'s instructions. The cut-off value of AFP for HCC was set at 20 ng/mL. Alanine aminotransferase (ALT) concentrations were determined using a kinetic method (Zhejiang Elikan Biological Technology Company, Limited, Wenzhou, Zhejiang, China).

Nested PCR for HBV DNA and nucleotide sequencing
------------------------------------------------

HBV DNA was extracted from 85 μl serum by pronase digestion followed by phenol/chloroform extraction. The method for amplification and sequencing of the BCP region has been reported previously [@B8].

Genotyping in GWAS
------------------

Peripheral blood mononuclear cell (PBMC) DNA was extracted from 200 μl blood using a QIAamp^®^DNA Mini Kit. PBMC DNA was sent to the CapitalBio Corporation (Beijing 102206, China) for genotyping. The Infinium® HumanCore BeadChips (Illumina Inc.) was used for genotyping 306670 SNPs in the GWAS stage. For the genotyping reactions, 250 ng of genomic DNA was analyzed using the Infinium® Human Core Bead Chips according to the manufacturer\'s recommendations and using their reagents [@B19]. Infinium® HumanCore BeadChips Genotype data were generated using GenomeStudio Genotyping Module v1.0. The genotyping was performed by laboratory personnel blinded to the study subjects.

SNP selection and genotyping in the replication study
-----------------------------------------------------

If a locus had a SNP with a P value \<1.0 × 10^-4^ in the GWAS stage, it was chosen for replication. If several SNPs were in the linkage disequilibrium with R^2^\>0.6, the SNP with the lowest P value was selected. The iPLEX MassARRAY platform (Sequenom Inc.) was used in the replication stage. 50 ng of genomic DNA was analyzed using the iPLEX MassARRAY platform according to the manufacturer\'s recommendations and using their reagents [@B19]. iPLEX MassARRAY platform Genotype data were generated using MassARRAY® Typer 4.0 software. The genotyping was performed by laboratory personnel blinded to the study subjects.

Functional annotation and differential expression analysis
----------------------------------------------------------

Whole blood was collected in EDTA tubes and RNALock Reagent (TIANGEN, China) was added immediately. Total RNA was extracted from the PBMC using RNAprep Pure Blood Kit (TIANGEN, China) according to manufacturer\'s instructions. The RNA was reverse transcribed as PCR template using a PrimeScript^TM^ II 1st Strand cDNA Synthesis Kit (TaKaRa, China), followed by PCR with SYBR Premix Ex Taq^TM^ II (TaKaRa, China). The expression of mRNA was detected by quantitative real-time reverse transcriptase PCR (qRT-PCR) on CFX96 (BioRad). The primers used for GAPDH, CARD6, PTGER4 and C7 were GAPDH-2F (5\' GAAGGTGAAGGTCGGAGTC 3\') and GAPDH-2R (5\' GAAGATGGTGATGGGATTTC 3\'), CARD6-F (5\' CCCACTGTGCTTGTATCTGC 3\') and CARD6-R (5\' CGGTAGCCATTGTTCCTGT 3\'), PTGER4-F (5\' CGCAAGGAGCAGAAGGAGAC 3\') and PTGER4-R (5\'CAGGCTGAAGAAGAGCAGAATGAA 3\'), C7-2F (5\' AACGGCAAGGAGCAGACG 3\') and C7-2R (5\' TGTCCAGTGCCCAGTTGTG 3\'), respectively. GAPDH was chosen as an endogenous control to normalize the relative mRNA expression levels. Experiments were performed in duplicate for each sample and fold changes were calculated by the equation 2^-ΔΔCt^.

Statistical analysis
--------------------

The PLINK package [@B20] was used to carry out the quality control procedures and association analyses. Quality control (QC) procedures were carried out using GenomeStudio Genotyping Module v1.0. The exclusion criteria were minor allele frequency (MAF) \<0.04, SNP call rate \<90%, and deviation from Hardy-Weinberg Equilibrium (p \<0.05). Genetic association tests were carried out by multivariate analysis using logistic regression by entering variables in the PLINK software. Statistical comparisons of gene expression between cases and controls were performed carried out using a non-parametric paired*t* test (SPSS v.16.0). All *P* values were two-tailed and *P*\<0.05 was considered to be significant.

Results
=======

Genome-wide association analysis
--------------------------------

In the initial discovery stage, we conducted a GWAS using samples from 218 asymptomatic HBsAg carriers with BCP double mutations (cases) and 191 asymptomatic HBsAg carriers with the wild type BCP (controls). There are 122 males in the case group (56.0%) and 102 males in control group (53.4%). The average ages of the case and control groups are 50.8±6.3 and 51.0±6.5, respectively. There was no difference between the two groups in terms of sex (χ^2^ =0.274, *P*\>0.05) and age (*F* =1.974, *P*\>0.05) (Table [1](#T1){ref-type="table"}).

Quality control (QC) procedures were first applied to 409 individuals. All 409 study subjects passed the call rate of 90% and were used in the final statistical analysis. The exclusion criteria were minor allele frequency (MAF) \<0.05, SNP call rate \<90%, and deviation from Hardy-Weinberg Equilibrium (p \<0.05). Based on these criteria, 25296 SNPs were retained. The quantile-quantile plot for the cases and controls is shown (Figure [1](#F1){ref-type="fig"}). The genomic inflation factor for the cases and controls was 1.147, indicating adequate control of population stratification and systematic bias in our GWAS population. In the GWAS stage, we assessed genome-wide associations for the cases and controls using multivariate linear models adjusted with age and sex. We found that there are two regions with trends of significant difference. They located in Chromosomes 5 and 10.The strongest association signals was SNP rs2910830 in phosphodiesterase 4D (PDE4D), located on chromosome 5q12 (P=1.136 × 10^-5^) (Figure [2](#F2){ref-type="fig"}).

SNP selection and genotyping in the replication study
-----------------------------------------------------

A P value \<10^-4^ was considered to be statistically significant and selected for the replication stage. When several SNPs were in linkage disequilibrium with R^2^ \>0.6, the SNP with the lowest P value was selected. These parameters led to the identification of 45 candidate SNPs which were taken forward to the replication stage. The study subjects were 203 asymptomatic HBsAg carriers infected with HBV with BCP double mutations (case group) and 181 asymptomatic HBsAg carriers infected with HBV with wild-type BCP (control group). There are 102 males in the case group (50.2%) and 100 males in the control group (55.2%). The average ages of the case and control groups are 50.4±7.0 and 47.5±7.0, respectively. There are no significant differences between the two groups in terms of sex and age (Table [2](#T2){ref-type="table"}). Genotyping was carried out in the replication stage using the iPLEX MassARRAY platform (Sequenom Inc.). The primers and probes are available upon request. The laboratory technicians who performed the genotyping experiments were blinded to the status of case and control. Three SNPs were found to be differ significantly, rs7717457 (P=0.01387), rs670011 (P=0.04085) and rs2071611 (P=0.04627) (Table [3](#T3){ref-type="table"}).

We also carried out a combined analysis of data of the GWAS and replication studies, using multivariate linear models adjusted with age and sex. We found that rs7717457 (P= 4.57×10^-5^) reached the potential GWAS significance level. However, rs2910830 (P= 1.136×10^-5^), which had the most significant association at the GWAS stage, showed a *P* value of 6.53×10^-4^ when the data from the two stages were combined.

Differential expression analysis
--------------------------------

To determine whether the SNPs found to be associated with BCP double mutations in the GWAS stage and replication stage influence the expression of the corresponding genes, rs7717457, with the lowest P value among the three SNPs above, was selected for the analysis. The position of rs7717457 is near gene CARD6, gene complement component 7 (C7) and gene PTGER4 of 5p13.1. (<https://genome.ucsc.edu> and <https://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm>). Whole blood samples were collected from the Long An cohort, including 23 individuals infected with HBV with BCP double mutations (case group) and 28 individuals infected with BCP wild type (control group) (Table [4](#T4){ref-type="table"}). These study subjects differ from those in the GWAS stage and replication stage. We found that the expression of genes CARD6 and PTGER4 did not differ significantly between the two groups. However, the difference in the expression of gene C7 between the case group (1.99) and control group (4.10) was significant (t=2.045, P=0.04) (Figure [3](#F3){ref-type="fig"}), suggesting that human genes are involved in selecting viral mutations.

Clinical significance of the SNPs
---------------------------------

We randomly tested the serological parameters of HBV, ALT and AFP for 196 study subjects from the GWAS and replication stages. No association between the rs7717457 mutations and sex, HBeAg, ALT or AFP was found (Table [5](#T5){ref-type="table"}).

Discussion
==========

The major findings of this study are that three SNPs were found to be associated with HBV BCP double mutations in the replication stage, rs7717457, rs670011, rs 2071611. rs7717457 may influence the expression of its nearest gene, C7, suggesting that human genes are involved in selecting viral mutations. No association was found between rs7717457 and sex, HBeAg, ALT or AFP. A strength of this study is that the study subjects in the GWAS were recruited from a long-term cohort, which provides reliable information for each study subject, such as the status of the BCP sequence of HBV. A weakness of the study is that the sample size is small, which may prevent some interesting SNPs being found. Another weakness is that the subjects of the GWAS and replication studies are all from the same ethnic minority, although they are not the same subjects. Therefore, we do not know whether the findings are applicable to other ethnic populations.

The lack of a proof-reading activity of the viral polymerase leads to a high rate of mutation during replication of the HBV genome. Some of these mutants may become predominant strains but others not, and some predominant strains have clinic significance. The question is which mutants can become predominant strains; more than 60% of the mutations are subject to selection forces from host immune surveillance, antiviral therapy and replication fitness [@B21]. So the common explanation is the active adaptive evolution of mutant strains under various selection pressures, such as from immunoglobulin [@B22], immunization [@B23] or antiviral therapy [@B24]. However, these mutants may also occur naturally [@B25]. Clearly, the mechanism remains obscure. It also has been reported that HBV adapts to increasing immune pressure through preferential mutations in B-cell epitopes and by replicative attenuation [@B26]. The human leukocyte antigen (HLA) class I was found to be involved in this selection [@B27]. A candidate-gene study reported that rs2233406 variant genotypes significantly increased the frequencies of BCP double mutations and rs28362491 significantly increased the frequency of BCP double mutations but reduced the frequency of preS2 start codon mutations [@B17]. In this study, we are the first to use GWAS to find another SNP associated with double mutations in the core promoter of HBV. Furthermore, we found that this SNP influenced the expression of its nearest gene.

In this study, we found in the second stage three SNPs, rs7717457, rs670011 and rs2071611, are associated with the selection of double mutations in the core promoter of HBV. SNP rs2071611 is located in the intron region of gene KRT38 of 17q21.2. The protein encoded by gene KRT38 is a member of the keratin gene family [@B28]. The rs670011 was located between gene HIST1H2APS2 and gene SLC17A2 of 6p22.2. As a type I hair keratin, it is an acidic protein which heterodimerizes with type II keratins to form hair and nails. Gene HIST1H2APS2 is a histone pseudogene [@B29]. Gene SLC17A2 encodes an Na (+)-phosphate cotransporter 3 (NPT3) [@B30]. It seems that these SNPs are unlikely to influence the selection of double mutations in core promoter of HBV, considering the proteins encoded by the nearby genes.

rs7717457 is near gene CARD6, gene C7 and gene PTGER4 of 5p13.1. The expression of genes CARD6 and PTGER4 were not found to differ significantly between the groups with BCP double mutations (cases) and BCP wild type (controls), suggesting that the genes CARD6 and PTGER4 could not influence the selection of BCP double mutations. However, the difference in the expression of gene C7 between the two groups was significant, suggesting that rs7717457 is involved in selecting viral mutations. It has been reported that SNP can alter gene expression by affecting transcription rate because of altered transcription factor binding [@B31]. Therefore, the mechanism by which rs7717457 influences the expression of C7 gene requires study, which is important to understand the mechanisms of oncogenesis of HBV.

Gene C7 encodes a serum glycoprotein that forms a membrane attack complex, together with complement components C5b, C6, C8, and C9, as part of the terminal complement pathway of the innate immune system. The protein encoded by this gene contains a cholesterol-dependent cytolysin/membrane attack complex/perforin-like (CDC/MACPF) domain and belongs to a large family of structurally related molecules that form pores involved in host immunity and bacterial pathogenesis. This protein initiates membrane attack complex formation by binding the C5b-C6 subcomplex and inserts into the phospholipid bilayer, serving as a membrane anchor [@B32]-[@B34]. Mutations in this gene are associated with a rare genetic disorder, C7 deficiency [@B35]. It has been reported that complement component 7 (C7) is a potential tumor suppressor [@B36]. The reduced expression of C7 mRNAs may be associated with oesophageal tumorigenesis [@B37]. Complement proteins C7 and complement factor H (CFH) may control the stem of liver cancer cells via LSF-1[@B38]. Therefore, clearly, on one hand, SNP rs7717457 is associated with in the selection of BCP double mutations. On another hand, it may be involved in liver tumorigenesis. This may be an important finding towards understanding the mechanisms of oncogenesis of HBV BCP double mutations. This is also important because only a small fraction of asymptomatic HBsAg carriers with BCP double mutations go on to develop HCC, so the ability to predict those at highest risk may permit a more \'personalized\' screening strategy, and probably earlier intervention or treatment, and hence will be of great clinical relevance.

Although no association was found between rs7717457 and sex, HBeAg, ALT or AFP in our study, more clinical markers could be used for exploring for association between rs7717457 and HBV viral load, HCC status, cirrhosis, end-stage liver disease, etc.

In summary, our study provides evidence using GWAS that host genetic polymorphisms are associated with the immune selection of HCC-related double mutations (A1762T and G1764A) in the basal core promoter of HBV. We also found that this SNP, rs7717457, influenced the expression of its nearest gene, which has been reported to be involved in the control stemness of liver cancer cells. These results are important in furthering our understanding of the mechanisms of oncogenesis of HBV. In the future, the rates of SNP rs7717457 should be determined among patients with HCC, liver cirrhosis and chronic hepatitis, which will be helpful to understand further the mechanisms of oncogenesis.
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###### 

General characteristics of the study subjects in the GWAS

  Variables         Total          Cases           Control        P value
  ----------------- -------------- --------------- -------------- -----------
  Number            409            218             191            
  Male              224            122             102            *P*=0.604
  Female            185            96              89             
  Age, Years        50.9±6.4       50.8±6.3        51.0±6.6       *P*=0.782
  Abnormal ALT, %   9.3 (38/409)   10.1 (22/218)   8.4 (16/191)   *P*=0.551
  AFP (+), %        4.9 (20/409)   5.5 (12/218)    4.1 (8/191)    *P*=0.538

Abnormal ALT: ≥40 IU/ml, AFP (+): \>20 μg/L.

###### 

General characteristics of the study subjects in the replication study

  Variables         Total          Cases          Control         P value
  ----------------- -------------- -------------- --------------- -----------
  Number            384            203            181             
  Male              202            102            100             *P=*0.327
  Female            182            101            81              
  Age, Years        49.0±7.1       50.4±7.0       47.5±7.0        *P*=0.001
  Abnormal ALT, %   2.3 (9/384)    1.5 (3/203)    3.3 (6/181)     *P=0.235*
  AFP (+), %        3.4 (13/384)   4.9 (10/203)   1.7 (3/181)     *P*=0.08
  HBeAg (+)         6.0 (23/384)   0              12.7 (23/181)   *P*=0.001

Abnormal ALT: ≥40 IU/ml, AFP (+): \>20 μg/L.

###### 

Results of replication study for forty-five significant SNPs.

  CHR   SNP          BP          OR(GWAS)   OR       P(GWAS)       P value   P-hwe      A1   A2
  ----- ------------ ----------- ---------- -------- ------------- --------- ---------- ---- ----
  5     rs2935623    2767442     0.3544     1.448    0.0006732     0.2235    1          G    A
  5     rs7717457    40887679    1.725      1.466    0.000469      0.01387   0.305      G    A
  5     rs16887016   57501466    1.829      1.095    0.0009644     0.6009    0.04854    C    T
  5     rs7703245    60034662    0.482      0.8695   0.00006463    0.4721    0.8108     T    C
  5     rs10940659   60064514    0.49       0.8695   0.0001595     0.4721    0.8108     A    G
  5     rs1588265    60073967    0.482      1.018    0.00006463    0.9259    1          A    G
  5     rs4700365    60131915    0.5        0.8132   0.0007128     0.3381    0.577      A    C
  5     rs1544791    60143255    0.5108     0.87     0.0004244     0.5163    0.5777     C    T
  5     rs983280     60149310    0.4767     0.9854   0.00005486    0.9397    1          T    C
  5     rs2910830    60171370    0.4365     0.9605   0.00001136    0.8298    0.6397     A    G
  5     rs2910829    60174072    0.4606     0.8797   0.00007343    0.5162    1          A    G
  5     rs4235479    60248826    0.5541     1.186    0.0009699     0.3299    0.4829     C    T
  5     rs35247      68715157    2.161      1.252    0.0003169     0.3384    0.6982     T    C
  5     rs10057967   75701931    1.701      1.105    0.0005652     0.492     0.7575     T    C
  5     rs27135      76717018    0.5228     1.064    0.00008475    0.7675    4.36E-07   G    A
  5     rs253061     76718175    0.5718     1.006    0.0008246     0.973     0.4289     C    A
  5     rs9293505    88890652    1.96       1.268    0.0006696     0.2523    0.7528     T    G
  5     rs17085231   95886452    1.662      1.023    0.0004618     0.8803    0.5238     T    C
  5     rs11741590   95905423    1.627      0.8981   0.0006059     0.4685    0.8801     T    C
  5     rs7707391    103613967   0.5803     1.219    0.000974      0.2356    0.007409   T    G
  5     rs246430     143602616   0.2891     1.321    0.0004727     0.3539    1          A    C
  5     rs3756309    150126061   1.93       1.102    0.0008312     0.6101    0.2895     C    T
  5     rs13166904   160940790   0.5477     0.9373   0.0003813     0.7185    0.4022     T    C
  5     rs17066036   165873965   0.5401     1.061    0.0001008     0.7235    0.452      A    C
  5     rs1445844    179080269   2.914      1.129    0.0003181     0.5991    0.4727     A    G
  5     rs1136377    179086140   2.892      1.135    0.000349      0.5798    0.4727     C    T
  6     rs4712415    19524844    0.6175     0.9775   0.0006521     0.8843    0.2958     T    C
  6     rs2743582    19525822    0.5086     0.853    0.0002772     0.4193    1          T    C
  6     rs1165159    25864397    2.093      1.322    0.00004903    0.3529    1          G    A
  6     rs670011     25887731    0.6324     1.378    0.0002081     0.04085   0.4132     A    C
  6     rs1150658    26098527    0.5641     0.8705   0.0001346     0.4634    0.03195    T    C
  6     rs707898     26116992    0.5634     0.8873   0.0001342     0.5196    0.08859    C    T
  6     rs198828     26119231    0.559      1.042    0.000004639   0.7854    0.7536     A    G
  6     rs6457736    33596635    2.135      1.042    0.000546      0.9035    0.335      C    T
  6     rs9365246    161056632   1.571      0.9879   0.0003458     0.938     0.5261     G    A
  6     rs2981977    167336662   0.582      1.045    0.00102       0.82      1          G    A
  10    rs11253241   5579665     0.5802     0.9532   0.0007793     0.7643    0.3643     T    C
  10    rs11005046   55827304    1.786      0.7658   0.0001032     0.08212   0.8746     C    A
  10    rs7908845    55887821    1.817      0.8838   0.0001392     0.4034    0.5379     C    T
  10    rs1245907    109768722   2.036      1.08     0.00001174    0.6255    0.4795     A    G
  10    rs7916801    109872687   1.941      1.088    0.00001864    0.59      0.8661     A    G
  10    rs9422853    126909164   1.649      1.073    0.0006043     0.6393    0.2301     G    A
  10    rs10781564   131944418   0.5955     0.9054   0.0005059     0.5081    0.8805     G    A
  10    rs7098827    131984924   0.4858     0.8068   0.0007101     0.3734    0.7227     T    G
  17    rs2071611    41439409    0.482      0.6775   0.00006463    0.04627   0.8168     T    A

CHR: Chromosome; SNP: single nucleotide polymorphism; BP: base-pair position; OR: odds ratio; P-hwe: P value for Hardy-Weinberg equilibrium; A1 and A2 are Allele, A1 is mutant and A2 is wild type. MAF: minor allele frequency. GWAS: OR and P from genome-wide association study.

###### 

General characteristics of the study subjects in the differential expression study

  Variables         Total        Cases        Control      P value
  ----------------- ------------ ------------ ------------ -----------
  Number            51           23           28           
  Male              35           17           18           *P*=0.46
  Female            16           6            10           
  Age, Years        46.0±4.7     49.5±4.5     46.0±4.7     *P*=0.01
  Abnormal ALT, %   3.9 (2/51)   8.7 (2/23)   0            *P*=0.111
  AFP (+), %        0            0            0            *P*=1
  Viral loads       8.49×10^4^   1.06×10^5^   6.72×10^4^   *P*=0.58

###### 

The distribution of SNP rs7717457 according to the characteristics of the study subjects

  -----------------------------------------------------------------------------------------------------------------
                   Number of study subjects   Allele\   Allele\        Rate of (A+G or G+G) (%)   X^2^    P value
                                              (A+A\*)   (A+G or G+G)                                      
  ---------------- -------------------------- --------- -------------- -------------------------- ------- ---------
  Sex                                                                                                     

  Male             102                        78        24             23.5                       0.439   P=0.508

  Female           94                         68        26             27.7                               

  HBeAg(-)         184                        137       47             25.5                       0.002   P=0.967

  HBeAg(+)         12                         9         3              25.0                               

  ALT \<40 IU/ml   191                        145       46             24.1                       8.017   P=0.005

  ALT≥40 IU/ml     5                          1         4              80.0                               

  AFP \<20 μg/L    189                        141       48             25.4                       0.036   P=0.967

  AFP ≥20 μg/L     7                          5         2              28.6                               
  -----------------------------------------------------------------------------------------------------------------

\* Allele (A+A) is wild type and A or G signifies the nucleotide.
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